

Help Shape the Future of Care at Glaucoma 360's New Horizons Forum

Meet your colleagues in San Francisco on February 3rd.

It's been called the "ultimate networking event" for anyone interested in creating a world free from glaucoma, and it's happening in February 2023 in San Francisco. Register now and be there to learn how the latest innovations in glaucoma care are evolving from brilliant ideas into groundbreaking diagnostics, devices, and therapies.

Are you interested in exploring new frontiers in glaucoma care? Looking to participate in real-time brainstorming with real-world patient impact? Curious about breaking news in vision restoration and neuroprotection? Then don't miss 2023's New Horizons Forum, the annual meeting-of-the-minds at the center of Glaucoma Research Foundation's annual Glaucoma 360 event, slated for February 3, 2023.

Held early each year over the course of 3 days, Glaucoma 360 is part clinician conference, part patient support summit, part innovation think-tank, and part festive fundraising gala, all focused on eliminating the second leading cause of blindness.¹ Glaucoma Research Foundation sponsors the event to advance scientific discovery, translate innovative ideas into care solutions, empower clinicians and patients, and build momentum toward its ultimate goal: curing glaucoma.

Unique in the realm of eye-science conferences, the New Horizons Forum is a cornerstone of Glaucoma 360. Attracting nearly 400 participants annually, the gathering unites people from across the innovation spectrum in a day packed with informative presentations, inspiring discussions, and rare informal networking opportunities. Clinicians, industry leaders, entrepreneurs, venture capital financiers,



Figure 1. Malik Kahook, MD, chief of the Sue Anschutz-Rogers Eye Center at the University of Colorado School of Medicine, will be delivering the keynote lecture at the 2023 New Horizons Forum in San Francisco.

FDA representatives, key opinion leaders, and glaucoma patients all meet, learn, share ideas, and collaborate at the only event of its kind, aimed at speeding sight-saving innovations to market.

SUSTAINED DRUG DELIVERY: FROM PROMISE TO REALITY

New Horizons has a history of attracting clinicians, scientists, and innovators in the vanguard of next-generation care, and 2023 will be no exception. Keynote speaker Malik Kahook, MD, Chief of the Sue Anschutz-Rogers Eye Center at the University of Colorado School of Medicine, is a true glaucoma visionary, passionate about advancing new care options. Dr. Kahook holds numerous patents in ophthalmology, including for the Kahook Dual Blade (New World Medical), which is one of the most commonly used devices for glaucoma surgery today. His off-campus incubator, Spyglass Ophthalmics, constantly investigates ways to serve glaucoma patients through new devices and better long-term drug-eluting platforms.

In his keynote presentation, Dr. Kahook will shed light on advances in drug delivery



Figure 2. Kristen Ingenito, MBA, Vice President of Market Scope, will provide an update on the market data of interventional glaucoma treatments within the ophthalmology marketplace, a popular session at the 2022 New Horizons Forum.

that will soon surpass current therapies in impact (Figure 1). "Today, intraocular pressure is the only modifiable risk factor for glaucoma,² and we have very powerful medications commercially available," says Dr. Kahook. "But patient adherence to prescribed therapies is low. Forgetfulness, physical limitations, adverse events associated with therapy — all are barriers to taking medications regularly. Finding new ways to deliver therapies, independent of patient dosing, with fewer ocular and periocular side effects, would greatly enhance care outcomes and decrease the burden of glaucoma. Clinicians would be empowered to deliver needed therapy, and patients would encounter fewer obstacles to receiving the care they need."

A regular participant in New Horizons, Dr. Kahook looks forward to showcasing

Learn more and register for all Glaucoma 360 events, including two no-fee continuing education programs, at glaucoma360.org.

STELLAR STEERING COMMITTEE SETS THE PACE

Each New Horizons Forum kicks off months before the event itself as steering committee members brainstorm on an agenda that reflects what's happening now in glaucoma care, what's on the horizon, and who has insider perspective. The list of committee members offers just a sample of the diversity of expertise represented at each event:

ADRIENNE L. GRAVES, PHD (CO-CHAIR)

- Co-Founder, Co-Chair, Chairman: Iveric Bio; Board of Directors: Glaucoma Research Foundation, Nicox S.A., Opus Genetics, Oxurion, Greenbrook TMS NeuroHealth, Surface Ophthalmics, Qlaris Bio, and TherOptix
- Durham, North Carolina

ANDREW IWACH, MD (CO-CHAIR)

- Executive Director, Glaucoma Center of San Francisco
- San Francisco

RANYA HABASH, MD

- CEO, LifeLong Vision; Microsoft AI for Health; FDA Digital Health Network of Experts; Chief Medical Officer, Everbridge; Medical Director, Technology Innovation and Assistant Professor of Ophthalmology, Bascom Palmer Eye Institute
- Miami

L. JAY KATZ, MD

- Director Emeritus Glaucoma Service, Wills Eye Institute; Professor of Ophthalmology, Thomas Jefferson University
- Philadelphia

INDER PAUL SINGH, MD

- President, The Eye Centers of Racine & Kenosha
- Racine, Wisconsin

RUTH D. WILLIAMS, MD

- Glaucoma Specialist, Wheaton Eye Clinic
- Wheaton, Illinois

“GLAUCOMA IS ONE OF THE MOST INTERESTING SPACES WITHIN OPHTHALMOLOGY. THERE’S SO MUCH WORK BEING DONE TO DEEPEN OUR UNDERSTANDING OF THE DISEASE, AND SO MUCH INNOVATION HITTING THE MARKET FOR DIAGNOSTICS, CARE, AND PROCEDURES.”

**— KRISTEN INGENITO,
VICE PRESIDENT, MARKET SCOPE**

discoveries that will enhance patient care going forward. “I love that the audience for this meeting includes industry, doctors, and patients, and that the focus is on discussing new ways to treat this blinding disease,” he says. “It’s the single best meeting for learning about emerging companies in the field and interacting with passionate people across the entire glaucoma ecosystem.”

BRINGING NEW CARE OPTIONS TO PATIENTS TODAY

This year, New Horizons will include an illuminating discussion led by Kristen Ingenito, MBA, Vice President of Market Scope (Figure 2). Headquartered in St. Louis, Market Scope is a leading source for market data, independent perspective, and objective analysis in today’s ophthalmology marketplace. Ms. Ingenito tracks and interprets the latest developments in diagnostics, devices, and drug delivery and has a birds-eye view of innovations on the horizon.

In San Francisco, Ms. Ingenito will share her perspective on evolving glaucoma care options, starting with how glaucoma fits, from an industry perspective, into the overall ophthalmology market. “Generic interventional glaucoma treatments — canal-based therapy, MIGs, stents — are the fastest-growing segment in ophthalmology,” she says. “That’s very exciting news for industry, entrepreneurs, clinicians, and glaucoma patients.”

Ms. Ingenito will also shed light on opportunities and challenges in each glaucoma market segment — diagnostics, pharmaceuticals, devices — with a focus on which areas are growing, why, and what growth looks like. “This year we’re seeing a lot of activity in the procedures market,”

Ms. Ingenito says. “We’ll break down that trend and look at how the changing demographics of care providers — not just glaucoma specialists — affect the market.”

Another key topic will be changing treatment paradigms — mixing and matching procedures and pharmaceuticals. “What does that trend look like as science evolves? And how does it tie in with progress on the digital side — for example, using the iris registry and other data to change treatment paradigms and serve patients better?” says Ms. Ingenito.

Having FDA and industry representatives in the room is a key distinction of New Horizons, making the forum especially meaningful for clinicians looking to stay on the leading edge of care. “If you’re a clinician, it’s very important to understand what industry is focused on as well as what regulators require for bringing innovations to market. One of the greatest advantages to attending New Horizons is being able to hear the rich discussion that happens among presenters, panelists, and audience members,” Ms. Ingenito says. “You don’t find that at other conferences, and you won’t want to miss it.” ■

Glaucoma 360 kicks off February 2nd at San Francisco’s iconic Westin St. Francis Hotel. The New Horizons Forum is held on February 3rd.

1. Centers for Disease Control and Prevention. Don’t let glaucoma steal your sight! Centers for Disease Control and Prevention. Available at: <https://www.cdc.gov/visionhealth/resources/features/glaucoma-awareness.html#:~:text=Glaucoma%20is%20a%20group%20of,results%20in%20increased%20eye%20pressure>. Accessed: November 1, 2022.

2. Coleman AL, Miglior S. Risk factors for glaucoma onset and progression. *Surv Ophthalmol*. 2008. 53 Suppl1:S3-10.